LexDanaLexDanabeta
Inventor

Mark Smith

Inventor
San Francisco, CA, US

Overview

38→
Patents
2002–2020
Patent span
Chemistry
Primary field (CPC C)

Patents· 38 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations19%
A61KPreparations for medical, dental or toiletry purposes16%
C07HSugars14%
C07DHeterocyclic compounds11%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms9%
Y02PClimate change mitigation technologies in the production or processing of goods9%
B01JChemical or physical processes, e.g. catalysis or colloid chemistry4%
C08FMacromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds4%
C40BCombinatorial chemistry4%
Y10TTechnical subjects covered by former us classification4%
PatentTitleYear
10,682,3694'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication202010,548,982Reversible covalent linkage of functional molecules202010,525,437Methods and compositions of localizing nucleic acids to arrays202010,513,731Modified nucleotides201910,358,4584'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus RNA replication201910,174,094Reversible covalent linkage of functional molecules201910,092,6494'-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication201810,010,623Lysosome-cleavable linker20189,926,309'Pi-kinase inhibitors with anti-infective activity'20189,895,442'4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication'20189,889,422'Methods of localizing nucleic acids to arrays'20189,708,357'4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication'20179,694,028'4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication'20179,505,758'Substituted 1,5-naphthyridines as endonuclease inhibitors'20169,434,745'7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease'20169,388,464'Modified nucleotides'20169,376,710'Methods of localizing nucleic acids to arrays'20169,370,569'4′-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza RNA replication'20169,295,729'Reversible covalent linkage of functional molecules'20169,249,176'4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication'20169,199,987'Substituted naphthyridines for the treatment, amelioration or prevention of a viral disease'20159,121,060'Modified nucleotides'20159,045,486'Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease'20158,969,258'Methods of localizing nucleic acids to arrays'20158,952,039'Pyridone derivatives and their use in the treatment, ameloriation or prevention of a viral disease'20158,921,388'Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease'20148,597,881'Modified nucleotides'20138,563,477'Modified molecular arrays'20138,071,739'Modified nucleotides'20117,947,709'Non-nucleoside reverse transcriptase inhibitors'20117,771,973'Modified nucleotides'20107,625,897'Non-nucleoside reverse transcriptase inhibitors'20097,541,444'Modified nucleotides'20097,378,402'Anti-viral nucleosides'20086,846,810'Antiviral nucleoside derivatives'20056,593,489'Substituted cyclopentenes, their preparation and their use for chiral scaffolds'20036,462,091'Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications'20026,458,851'Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications'2002

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2005–2019Based in San Francisco, CA, US· patent location history
2009–2020Patents assigned to ILLUMINA CAMBRIDGE LTD (12)· patent assignee history
2009–2019Based in Saffron Walden, GB· patent location history
2013–2020Based in Walden, GB· patent location history
2014–2016Patents assigned to HOFFMANN LA ROCHE (6)· patent assignee history
2014–2016Patents assigned to SAVIRA PHARMACEUTICALS GMBH (6)· patent assignee history
2014–2015Patents assigned to EUROPEAN MOLECULAR BIOLOGY LAB EMBL (4)· patent assignee history
2014–2016Based in Jersey City, NJ, US· patent location history
2016–2020Patents assigned to RIBOSCIENCE LLC (8)· patent assignee history
2016–2020Based in London, GB· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ILLUMINA CAMBRIDGE LTD122009–2020
RIBOSCIENCE LLC82016–2020
HOFFMANN LA ROCHE62014–2016
SAVIRA PHARMACEUTICALS GMBH62014–2016
EUROPEAN MOLECULAR BIOLOGY LAB EMBL42014–2015
Locations
LocationPatentsSpan
San Francisco, California, US122005–2019
Saffron Walden, GB72009–2019
Jersey City, New Jersey, US62014–2016
Walden, GB52013–2020
London, GB42016–2020